Astal Laboratories opened at ₹61.67, in line with its previous close of ₹61.66. During today's session, the stock has traded between ₹61.41 and ₹64.75, with an average traded price of ₹62.50. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Astal Laboratories is now worth
₹ 73,830.00
Giving a profit of
₹ 63,830.00 (638.30%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.16 (-0.26%)
Day High
₹64.75
Day Low
₹61.41
Day Open
₹61.67
Prev Close
₹61.66
Volume
8,481
Value Traded
₹0.05 Cr
1W Return
2.01%
1M Return
-6.82%
3M Return
-28.89%
6M Return
-25.27%
1Y Return
-32.37%
Market Cap (₹ Cr.)
269
PE Ratio
18.40
PB Ratio
0.80
Dividend Yield
-
ROE
4.41%
ROCE
5.58%
Book Value (₹)
77.17
Face Value (₹)
10.00
EPS (TTM)
2.19
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
2.01%
6 Weeks
-
1 Month
-6.82%
3 Months
-28.89%
9 Months
-23.30%
Astal Labs subsidiary appoints internal, cost and secretarial auditors for FY27
Astal Laboratories' subsidiary Sriven Pharmachem appointed three auditors for FY27. Mr. Balayogiswara Rao Peddinti named internal auditor; M/s Avnesh Jain & Co. as cost auditor. M/s Mahendra Khandelwal & Co. appointed as secretarial auditor to enhance compliance.
1mo agoAstal Laboratories adopts FY26 financials at 33rd AGM
Astal Laboratories Limited held its 33rd AGM on September 29, 2026, via Video Conferencing. Shareholders adopted standalone and consolidated audited financial statements for FY26. Maggidi Venkatesh was re-appointed as Non-Executive Director after retiring by rotation. Thirty-one members participated in the meeting, which concluded at 2:22 pm IST.
1mo agoAstal Laboratories promoter ACESO buys 25,417 shares on BSE
ACESO Research Labs LLP bought 25,417 Astal Laboratories shares. Transaction valued at ₹19,99,812 executed on BSE. Purchase period spanned August 24 to September 8, 2026. Promoter holding rose to 2,011,012 equity shares. No derivative trading reported by the promoter.
2mo agoAstal Laboratories schedules 33rd AGM for September 29, 2026
Astal Laboratories schedules its 33rd AGM for September 29, 2026. Remote e-voting window opens on September 26 and closes on September 28. Board approved FY26 financial results in September 4 meeting. Share transfer books close from September 23 to September 29.
2mo agoAstal Laboratories Q1 Results: Unaudited financials filed for June 2026
Astal Laboratories Limited filed its unaudited Q1FY26 standalone and consolidated financial results with BSE. The company confirmed publication in major newspapers on August 15, 2026, adhering to SEBI LODR Regulation 47. No specific financial figures were disclosed in this procedural filing.
2mo agoAstal Laboratories eyes pharma unit acquisition, plans Rs. 300 crore fundraise
Astal Laboratories Ltd has approved the evaluation of pharmaceutical manufacturing unit acquisitions in India, targeting USFDA, EU-GMP, or WHO/GMP compliant facilities to meet rising demand. The CFO has been authorised to raise up to Rs. 300 crore through convertible and non-convertible instruments via private placement, with the company's market capitalisation standing at Rs. 90 crore.
4mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹354.40 | -1.31% | ₹27,706.09 | 17.80 | +20.22% | |
| ₹288.35 | +0.23% | ₹20,097.73 | 28.10 | -21.29% | |
| ₹440.45 | +2.81% | ₹19,034.47 | 27.80 | +27.43% | |
| ₹1,558.70 | +0.60% | ₹14,659.69 | 20.10 | -30.53% | |
| ₹190.44 | -0.98% | ₹13,597.42 | 20.50 | +23.61% | |
| ₹690.60 | +0.47% | ₹9,590.38 | 96.30 | +12.74% | |
| ₹56.15 | +4.68% | ₹8,422.50 | 26.70 | -15.67% | |
| ₹1,067.70 | -0.39% | ₹7,523.01 | 18.80 | -15.95% | |
| ₹31.01 | -0.55% | ₹7,232.17 | 12.90 | +0.00% | |
| ₹151.25 | +1.34% | ₹6,927.84 | 63.50 | +24.74% | |
| ₹613.95 | -0.96% | ₹6,392.13 | 93.50 | +51.97% | |
| ₹519.90 | -0.21% | ₹5,946.67 | 105.40 | -11.11% |
An investment of ₹10,000 made 5 years ago in Astal Laboratories is now worth
₹ 73,830.00
Giving a profit of
₹ 63,830.00 (638.30%)
Note: Past profits do not guarantee future returns.
